Article

Genetics Figure in AMD's Onset and Progression

Author(s):

Genetic factors are at work in determining who gets age-related macular degeneration, and its progression, a German team reported.

Age-related macular degeneration (AMD) is common and can cause both visual impairment and blindness.

In a German study reported in PLOS researchers looked a the genetics of the condition.

They assigned 3,444 individuals with AMD to nine categories of severity based on the characteristics of each eye.

They then genotyped 18 single nucleotide polymorphisms (SNPs) and tried to correlate them with the severity stages.

The team found there are genetic factors at play.

“The association of known genetic risk factors with AMD became stronger with increasing disease severity, which also led to an increasing discriminative ability of AMD cases and controls,” wrote Tina Schick of the Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany, and colleagues, “Genetic predisposition was also associated with the disease severity of the fellow-eye, highlighting the importance of both eyes in AMD patients”.

The team’s research builds on earlier work by others done mostly in late-stage AMD.

“Our results support these findings in more detail and suggest that there is a disease continuum from early to late AMD based on genetic factors,” the authors noted.

They found that genetic risk variants primarily established for late AMD “showed reduced effects on early stages of the disease,” and that “associations of these variants with AMD became stronger with increasing disease severity, which also led to an increasing discriminative ability”

The results also underline the importance of the second eye in AMD patients because the genetic predisposition was also associated with the disease severity of the fellow-eye.

The findings could lead to developing treatments to prevent vision loss, but first researchers need to determine the processes that lead to the onset of early AMD, as well its progression.

Related Videos
A panel of 3 experts on dry eye
A panel of 3 experts on RVO
HCPLive Five at ASRS 2024 | Image Credit: HCPLive
Jordana Fein, MD: Pre-Dose IOP Outcomes After Aflibercept 8 mg for DME | Image Credit: LinkedIn
Diana Do, MD: Impact of Baseline BCVA on Aflibercept 8 mg Outcomes in DME | Image Credit: Stanford University
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.